VERA Vera Pharma: Earnings per share for the last twelve months

Vera Therapeutics, Inc. (VERA) utilizes an asset-light model with outsourced manufacturing and implements robotic protein screening to accelerate testing. Net income per share over the last four quarters illustrates the efficiency of these processes, with the indicator reaching -5.88. Consequently, the company develops targeted molecules that block the pathological immune response in severe kidney diseases.
Analytical breakdowns and data insights for company Vera Therapeutics, Inc. (VERA)

Net income per share (TTM) measures the final return of each security over a year, allowing investors to evaluate business capitalization efficiency and real cash flow growth rates. By analyzing the specific profit levels of Vera Therapeutics, Inc. (VERA) over 12 months, one can diagnose the company's transition toward monetizing innovative molecules for kidney treatment, which are protected by strong patent barriers in the orphan segment.